Nick Bilton, How Elizabeth Holmes’s House of Cards Came Tumbling Down. Vanity Fair, 6 September 2016. “In a searing investigation into the once lauded biotech start-up Theranos, Nick Bilton discovers that its precocious founder defied medical experts–even her own chief scientist–about the veracity of its now discredited blood-testing technology. She built a corporation based on secrecy in the hope that she could still pull it off. Then, it all fell apart.”
October 16, 2015
How Startup Theranos Has Struggled With Its Blood-Test Technology
John Carreyrou, How Startup Theranos Has Struggled With Its Blood-Test Technology. The Wall Street Journal, 16 October 2015. “On Theranos Inc.’s website, company founder Elizabeth Holmes holds up a tiny vial to show how the startup’s “breakthrough advancements have made it possible to quickly process the full range of laboratory tests from a few drops of blood.” The company offers more than 240 tests, ranging from cholesterol to cancer. It claims its technology can work with just a finger prick. Investors have poured more than $400 million into Theranos, valuing it at $9 billion and her majority stake at more than half that. The 31-year-old Ms. Holmes’s bold talk and black turtlenecks draw comparisons to Apple Inc. cofounder Steve Jobs. But Theranos has struggled behind the scenes to turn the excitement over its technology into reality. At the end of 2014, the lab instrument developed as the linchpin of its strategy handled just a small fraction of the tests then sold to consumers, according to four former employees.”
Winner of the 2015 George Polk Award for Financial Reporting. “The award for Financial Reporting will go to John Carreyrou of The Wall Street Journal whose investigation of Theranos, Inc. raised serious doubts about claims by the firm and its celebrated 31-year-old founder, Elizabeth Holmes, that its new procedure for drawing and testing blood was a transformational medical breakthrough in wide use at the firm’s labs. Carreyrou’s well-researched stories, reported in the face of threats of lawsuits and efforts to pressure some sources to back off of their accounts, led to a reevaluation of Theranos’ prospects among investors and have been followed by regulatory actions against the company and widespread discussion that publications and institutions from Fortune and The New Yorker to Harvard and the White House may have been too quick to hail Holmes, a Stanford dropout whose personal wealth at the height of her startup’s rise was an estimated $4.5 billion, as a success story in the tradition of Steve Jobs, Bill Gates and Mark Zuckerberg.”